Zithrodose

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zithrodose

Quick Facts

Property Description
Active ingredient Azithromycin (as dihydrate)
Form Tablets, Oral Suspension, Injection
Pharmacological class Macrolide Antibiotic (Azalide subclass)
Common use Resolution of bacterial infections
Origin Semi-synthetic (derived from Erythromycin)

What Type of Medicine is Zithrodose?

Zithrodose is a prescription medicine containing the active ingredient Azithromycin, which functions as a potent antibacterial agent. It is classified as an azalide, a distinct subclass of the broader macrolide antibiotic group. This structural designation is clinically recognized for conferring the benefits of high tissue penetration and a long half-life compared to older macrolide compounds. Azithromycin, as the drug's core component, is a semi-synthetic compound, having been structurally derived from the natural product Erythromycin.

Composition and Available Forms of Zithrodose

The composition of Zithrodose primarily features Azithromycin dihydrate as the therapeutic substance. Azithromycin is recognized as a highly effective macrolide agent. This supports the drug's role as a reliable option for fighting specific bacteria. Zithrodose is supplied across several key dosage forms, including the familiar film-coated tablets and a powder for oral suspension, which is particularly suitable for pediatric patients. The medicine’s delivery options also include a lyophilized powder for intravenous injection, allowing for both the oral and intravenous route of administration.

General Purpose of This Antibacterial Agent

The essential purpose of Zithrodose is to manage and resolve established bacterial infections caused by susceptible microorganisms. Its fundamental action is achieved through inhibiting the growth of bacteria, creating a bacteriostatic effect. This action helps the body control the population of disease-causing bacteria. The mechanism involves preventing the microbes from creating the proteins vital for their replication and survival, which aids the body’s immune system in clearing the underlying infection.

Regulatory References

  1. Azithromycin Drug Information

What side effects are possible with Zithrodose?

Possible side effects and safety information

The safety profile of Zithrodose (Azithromycin) is officially characterized by a spectrum of adverse reactions organized by frequency and system-organ class, as documented by regulatory agencies (e.g., FDA and EMA).

Commonly Documented Adverse Reactions

Adverse reactions classified as Very Common or Common are primarily related to the Gastrointestinal System, and may include loose stools or diarrhea, abdominal pain, nausea, and vomiting. Headache is also officially listed as a common effect. Reactions classified as Uncommon can affect the nervous system (e.g., dizziness, somnolence) and the skin (e.g., rash, angioedema).


Serious Adverse Reactions and Regulatory Focus

The official labeling highlights the potential for serious adverse reactions, particularly affecting the cardiovascular and hepatobiliary systems. Severe warnings concern the possibility of QT interval prolongation, which carries a documented risk of developing Torsades de pointes, a serious heart rhythm abnormality. Furthermore, rare but severe hepatotoxicity, including hepatic necrosis and failure, has been officially reported. Other serious effects include severe hypersensitivity reactions (such as DRESS and Stevens-Johnson Syndrome) and the potential for Clostridioides difficile-associated diarrhea (CDAD)

.


Population-Specific Safety Constraints

Specific regulatory constraints exist for certain populations. Zithrodose is contraindicated in patients with a known hypersensitivity to any macrolide or ketolide and in those with a history of cholestatic jaundice associated with prior azithromycin use. Caution is noted for use in patients with significant hepatic disease or severe renal impairment (GFR < 10 mL/min), due to the drug’s elimination characteristics. Older adults may have a higher documented susceptibility to the cardiac risks (Torsades de pointes) due to existing proarrhythmic conditions.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Zithrodose overdose emphasizes the need for immediate medical attention due to the potential for severe and life-threatening complications.

Documented Overdose Manifestations

Domain Official Regulatory Statement
Gastrointestinal Effects Exaggerated common side effects, specifically nausea, vomiting, diarrhea, and abdominal pain.
Cardiovascular Risk Potential for Prolonged QT interval, Torsades de pointes, and Arrhythmia.

Emergency Actions and Management

Regulatory labeling mandates specific steps when an overdose is suspected:

Classification Aspect Official Regulatory Statement
Severity Classification Overdose may be associated with severe, potentially fatal cardiac events.
Emergency Response Seek immediate medical attention. Contact a healthcare professional, hospital emergency department, or regional poison control center immediately.
Management Principle Management requires symptomatic and supportive measures, including necessary cardiac monitoring. No specific antidote is known.

Overdose Profile Summary

The official overdose statements are defined by the potential for exaggerated gastrointestinal complaints and the critical risk of life-threatening cardiac arrhythmias. Because no specific antidote is known, the official guidance mandates that management must focus on essential supportive measures and cardiac monitoring in a healthcare setting. This severity potential is the regulator-derived trigger for the explicit instruction to seek immediate medical attention when an overdose is suspected. Specific risk for serious cardiac outcomes is noted for patients with pre-existing cardiovascular disorders.

Therapeutic Uses of Zithrodose

Quick Facts: Therapeutic Areas

  • Respiratory Support: Used to manage community-acquired pneumonia and acute worsening of chronic bronchitis.
  • Skin and Tissue: Appropriate for certain uncomplicated skin and soft tissue infections.
  • Ear and Sinus: Provides management options for acute bacterial sinusitis and middle ear infections (acute otitis media).
  • Genital Infections: Utilized in the management of specific sexually transmitted infections involving the urethra, cervix, and genital ulcer disease.

Zithrodose is a prescribed medication intended for the management of infections caused by susceptible bacteria. Its uses are concentrated in several therapeutic domains across different parts of the body.

In the respiratory system, the drug is used as a therapeutic option for community-acquired pneumonia and for acute bacterial exacerbations of chronic bronchitis. It is also suitable for treating specific bacterial infections affecting the upper respiratory tract, such as acute bacterial sinusitis and certain cases of strep throat (pharyngitis/tonsillitis), typically when first-line options are not appropriate.

Zithrodose is also indicated for the treatment of uncomplicated infections of the skin and underlying tissues, and it is a key component in the management of select sexually transmitted infections, including those affecting the cervix and urethra. Additionally, the drug is used in pediatric patients for the management of acute otitis media. It is also used in combination therapy for the prevention and treatment of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infection.

Eligibility and Restrictions for Use

The official eligibility profile for Zithrodose (Azithromycin) is determined by regulatory agencies based on patient history, pre-existing conditions, and age.

Eligibility Scope

Category Regulatory Statement
Populations for whom use is contraindicated Individuals with known hypersensitivity to Azithromycin or any macrolide antibiotic. Patients with a history of cholestatic jaundice or liver dysfunction associated with prior Azithromycin use.
Age-related eligibility rules Safety and effectiveness have not been established for the treatment of patients under mathbf6 months of age for most indications. Pharyngitis/tonsillitis eligibility is not established for children younger than mathbf2 years of age.
Condition-specific eligibility rules Use requires caution in patients with severe renal impairment (GFR < 10 mL/min) or significant hepatic disease; use is often not recommended in severe cases. Caution is also advised for patients with known QT prolongation or Myasthenia Gravis.
Pregnancy and lactation eligibility status Use during pregnancy is advised only if clearly needed. The drug is excreted in human milk, requiring caution during lactation.

Eligibility Classifications

Official regulatory documents classify non-eligibility into Contraindicated (absolute prohibition) and Use with Caution/Not Recommended (conditional restriction). This structure is based on the specific risk to an organ system (liver, kidney, heart), hypersensitivity, or a lack of established safety data for certain age groups.

What should I know about interactions with other medicines?

Zithrodose's interaction profile is officially documented around pharmacokinetic and pharmacodynamic constraints. These documented interactions create conditions for co-administration, requiring strict constraint or therapeutic monitoring.

Contraindicated Combinations

Co-administration with ergot derivatives (e.g., Ergotamine, Dihydroergotamine) is strictly restricted due to the theoretical potential for ergotism. Additionally, the regulatory label advises caution with other QT-prolonging agents due to the documented additive risk of QT interval prolongation and subsequent ventricular arrhythmia.

Pharmacokinetic Alterations and Monitoring

The product may increase the plasma concentrations of certain co-administered drugs, such as Digoxin and Ciclosporin, necessitating therapeutic drug monitoring. Furthermore, the co-administration of Nelfinavir is documented to increase the systemic exposure of Azithromycin itself. A documented pharmacodynamic interaction exists with oral anticoagulants (Coumarin-type), which may increase the anticoagulant effect and requires close monitoring of prothrombin time.

Timing-Based Restrictions

Co-administration with antacids containing aluminum or magnesium is restricted, as it reduces the peak plasma concentration ( C max) of Azithromycin. These medicines must be separated by at least one hour before or two hours after the Azithromycin dose. Food administration is documented to increase the C max of the oral suspension but does not affect the total exposure.

Mechanism of Action

The action of Azithromycin is defined by two primary biological mechanisms that operate simultaneously: the inhibition of microbial growth and the modulation of the host's inflammatory response.

Ribosomal Blockade Halts Bacterial Replication

The drug acts as an inhibitor of essential protein synthesis in susceptible bacteria by binding to the 23S ribosomal RNA of the 50S ribosomal subunit . The physical occlusion of the peptide exit tunnel stops the growth of the bacterial polypeptide chain, resulting in the arrest of the microbial replication process. This mechanism imposes a bacteriostatic effect, stabilizing the pathogen population, which facilitates the action of the host's immune system.

Immunomodulation and Anti-Inflammatory Signaling

Beyond its direct antibacterial effects, Azithromycin accumulates within immune cells like macrophages and modulates key intracellular signaling pathways (e.g., NF-kappaB). This interaction reduces the transcription and release of pro-inflammatory mediators, such as IL-8, thereby dampening the excessive localized inflammatory response. This targeted modulation reduces neutrophil influx and the destructive collateral processes associated with overwhelming inflammation.

Dosage and Administration Information

Official Administration Guidelines

Azithromycin (Zithrodose) is administered through the oral route, utilizing film-coated tablets or suspension, and via slow intravenous (IV) infusion for patients requiring initial parenteral therapy. Usage is defined by precise, short-term courses, with administration almost always structured as once daily (QD) dosing.


Labeled Dosing and Scheduling

Regimen Type Standard Adult Schedule Duration Pattern
5-Day Course 500 mg Day 1, then 250 mg Days 2-5 Short-term course
3-Day Course 500 mg once daily for 3 days Short-term course
Single Dose 1000 mg or 2000 mg total dose Single-day course
IV Regimen 500 mg once daily (minimum 2 days) Sequential therapy lead-in

Contextual and Procedural Instructions

Oral tablets and the standard suspension can generally be taken with or without food. However, specific extended-release oral suspensions must be taken strictly on an empty stomach (at least 1 hour before or 2 hours following a meal). The IV formulation requires the lyophilized powder to be reconstituted and diluted and then administered as a controlled infusion lasting a minimum of 60 minutes; it must not be given as a rapid bolus.

For pediatric patients, dosing is determined based on body weight (mg/kg) and varies by the indication and required duration. If an oral dose is missed, it should be taken immediately unless the next dose is near, and the subsequent doses should be maintained on the original schedule; the missed dose should never be doubled. No dose adjustments are required for patients with mild-to-moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zithrodose

Evidence for Respiratory and Ear Infections (CAP, AECB, AOM)

Research has explored the use of Zithrodose across various conditions characterized by acute or disruptive episodes in the lungs and ears. Studies focusing on Community-Acquired Pneumonia (CAP) primarily took the form of Randomized Controlled Trials (RCTs), which monitored outcomes such as the time required to achieve clinical stability and how symptoms evolved. For Acute Exacerbations of Chronic Bronchitis (AECB), long-term Prospective Cohort Studies monitored the use of the drug for prophylaxis (prevention). Findings from these studies describe patterns related to the frequency of future acute episodes. However, reports also described patterns related to the selection of bacteria with reduced susceptibility to macrolides.

Evidence for Skin and Genital Infections (STIs, Skin)

Studies for select Sexually Transmitted Infections (STIs) employed Randomized Controlled Trials examining single-dose regimens. The outcomes examined were related to microbiological cure at a test-of-cure visit. For uncomplicated urogenital infections, trials reported measurements of microbiological eradication. Findings for infections located in the rectum described microbiological outcomes that differed from those reported for the standard comparator used in the study.

Long-Term Studies and Uncertainty

The length of patient monitoring varied. For acute infections, follow-up durations were limited. For AECB prophylaxis, studies monitored patient responses over longer time periods (up to two years). This research monitored outcomes over time to assess long-term patterns, but certainty remains low regarding sustained findings. There is limited information for long-term outcomes concerning the development of antimicrobial resistance following the drug’s use across conditions. Research is ongoing to fully understand the contribution of the drug's non-antibacterial properties to reported outcomes.

Key Studies & References

  1. Disseminated Mycobacterium avium Complex: Adult and Adolescent OIs - NIH Clinical Info Guidelines

Frequently Asked Questions (FAQ)

Common questions about Zithrodose (FAQ)

Q: Is Zithrodose a strong antibiotic?

Official health information describes Zithrodose (Azithromycin) as a potent antibacterial agent. It belongs to a subclass of macrolide antibiotics recognized for its broad spectrum of activity and its high concentration within body tissues. This classification aligns with its described purpose of managing certain bacterial infections.


Q: How quickly should I expect Zithrodose to start working?

The medicine is characterized by a long terminal half-life of 68 hours. This pharmacokinetic characteristic is why the drug is retained in the body’s tissues for an extended period, which is the basis for its short treatment courses.


Q: Are there any specific foods I should avoid while taking Zithrodose?

For standard film-coated tablets and suspension, regulatory guidelines state the medicine can be taken with or without food. However, specific extended-release formulations must be taken on an empty stomach to ensure the medicine is properly absorbed. There are no general warnings about avoiding specific types of food.


Q: Can Zithrodose still work if I feel a bit better after just one day?

Official patient counseling information emphasizes the completion of the entire prescribed course. Antibiotics are used to manage infections caused by susceptible bacteria, and stopping treatment too early may lead to the reappearance of the infection and is a known factor in reduced effectiveness over time.


Q: Why is Zithrodose sometimes prescribed as a short-course treatment?

The rationale for using Zithrodose in short-course regimens is directly linked to its long half-life. This characteristic means the medicine is retained in body tissues for a significant time and is slowly released, maintaining its antibacterial presence long after the final dose is taken.


Q: Are there any reported long-term effects associated with Zithrodose use?

Regulatory documents indicate that while studies have monitored outcomes over time, there remains limited information concerning long-term safety, especially regarding the development of antimicrobial resistance. Official patient counseling information advises completing the entire prescribed course to avoid the reappearance of infection.


Q: What kind of infections is Zithrodose typically used to treat?

According to the official Indications for Use, this medicine is approved for treating specific bacterial infections. These generally include respiratory tract infections (like certain types of pneumonia), middle ear infections, infections of the skin, and certain sexually transmitted infections.


Q: Can Zithrodose interact with common blood pressure medications?

Regulatory warnings advise caution when Zithrodose is used alongside other QT-prolonging agents. This class of medicines includes some commonly prescribed heart rhythm and blood pressure medicines. Caution is advised because of the documented, additive risk of developing serious heart rhythm abnormalities.


Q: Does Zithrodose need to be taken at the exact same time every day?

The administration is structured as once daily (QD) dosing to ensure a consistent presence of the drug in the body. The regulatory text confirms that if a dose is missed, patients should return to maintaining the subsequent doses on the original schedule without instruction.


Q: Does Zithrodose affect the ability to drive or operate machinery?

Official product information states that there is no evidence to suggest that Azithromycin (Zithrodose) has an effect that would impair a patient's ability to drive or operate heavy machinery. Side effects such as dizziness or somnolence (sleepiness) are listed in regulatory documents.


Q: Is it common for Zithrodose to cause a metallic taste?

Official postmarketing reports have documented changes in the sense of taste in patients taking Zithrodose. These taste disturbances, which can include a bitter or metallic sensation and, in rare instances, a loss of taste, are usually reported as temporary.


Q: How long does Zithrodose stay in your system after the last dose?

Pharmacokinetic data indicates the medicine has a long terminal half-life of 68 hours. This characteristic means the drug is retained in the body’s tissues for an extended period, which is the basis for its use in short treatment courses.


Q: Does Zithrodose affect birth control pills?

Information suggests that some antibiotics, including Azithromycin, may potentially reduce the effectiveness of ethinyl estradiol (a component found in certain oral contraceptives). Official information about concurrent use with contraceptives is generally addressed by healthcare professionals.


Q: Can Zithrodose be used if a person is allergic to penicillin?

Zithrodose is a macrolide, a class structurally different from penicillin (beta-lactam). Regulatory information indicates no expected cross-reactivity between the two classes, making it a recognized alternative.


Q: Is Zithrodose considered a broad-spectrum antibiotic?

Yes, authoritative health information bodies classify Zithrodose (Azithromycin) as a broad-spectrum macrolide antibiotic. This term indicates that it is effective against a wide range of bacteria, including Gram-positive and Gram-negative organisms, as well as some atypical pathogens.


Q: Has Zithrodose been studied for use in older adults (seniors)?

Studies have been conducted in healthy elderly subjects (ages 65 and older) to compare their drug handling to that of younger adults. While some differences were observed, official findings describe the way the body handles the drug in older adults as generally similar to younger adults.


Q: Does alcohol consumption change how Zithrodose works in the body?

Although a major direct interaction is not reported, guidance related to general antibiotic use suggests avoiding alcohol. Official warnings about alcohol typically focus on its potential to worsen common side effects like nausea or dizziness.


Q: Why is it important to know who cannot use Zithrodose?

Official regulatory documents detail contraindications (who cannot use the drug) to define populations for whom its use carries a documented risk of serious adverse reactions, such as those with prior hypersensitivity or liver dysfunction.


Q: Do studies suggest Zithrodose can cause changes in vision?

Rare instances of blurred vision and decreased vision have been reported through official postmarketing experience data. While these effects are more commonly associated with specialized ophthalmic use, they have been reported occasionally following oral use.


Q: What are the general expectations for a patient taking Zithrodose?

The medicine is generally used according to a short-course, once-daily schedule for the purpose of managing a bacterial infection. General expectations include completing the full course as described by the physician and being aware of the possible safety warnings, particularly concerning heart rhythm abnormalities.

How should Zithrodose be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for azithromycin (Zithrodose) are based strictly on regulatory labeling to ensure product stability and safety.

Storage Conditions:

  • Temperature: Tablets and dry powder for suspension must be stored at controlled room temperature, generally between 15 C and 30 C (59 F and 86 F).
  • Handling: The standard reconstituted oral suspension must not be frozen. The extended-release oral suspension must not be refrigerated. All containers should be kept tightly closed and protected from excessive heat, moisture, and light.

Stability and Shelf-Life:

  • The standard oral suspension, once mixed, must be used within 10 days. The extended-release suspension must be consumed within 12 hours of mixing.

Disposal and Safety:

  • Keep all forms of the medication out of the reach of children.
  • Any expired or unused medication, including leftover liquid suspension, must be safely thrown away according to official government guidelines for pharmaceutical disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zithrodose found in:

A-Z Index: